Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.39 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786379 | 0.90 | CCR2 (0.42) | CCR2BTKMAP3K12 | |
| SCHEMBL13806857 | 0.88 | PDE4A (0.39) | SYKEIF2AK4PDE4APDE4BPDE4C | |
| SCHEMBL3788239 | 0.83 | MAP3K12 (0.47) | SYKTACR1EIF2AK4MAP3K12GPR119 | |
| SCHEMBL3779367 | 0.80 | CCR2 (0.41) | SYKTACR1CCR2BTKMAP3K12 | |
| SCHEMBL3782885 | 0.75 | CCR2 (0.36) | CCR2BTK | |
| SCHEMBL13011450 | 0.75 | CCR2 (0.46) | CCR2 | |
| SCHEMBL13806570 | 0.72 | CCR2 (0.36) | SYKTACR1CCR2BTKMAP3K12 | |
| SCHEMBL30328148 | 0.71 | FFAR4 (0.54) | SYKEIF2AK4GPR119MAPT | |
| SCHEMBL23867885 | 0.70 | MGLL (0.58) | SYKGPR119 | |
| SCHEMBL29469963 | 0.70 | MGLL (0.58) | SYKGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CYTOPATHFINDER, INC. (JP) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331298-A1 | Carboxamide Compounds and Their Use | CCR2, CCR1, CCR5 | SYK 933/4885TACR1 539/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.